Friday 6 November 2026 Export BEAM’s income statement to Excel — free account

Beam Therapeutics Inc.

Beam Therapeutics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $139.7 million, up 120.0% from fiscal 2024.

Revenue: −96.8%
EPS: −16.7%
Free cash flow: −29.5%

Quarter to September 2026, against a year earlier

26.26 0.39 +1.51%

Follow BEAM

Alert me

Market cap: $2.7B
P/E: 0.0×
Fwd P/E: −6.2×
Dividend yield: —
F-score: 4/9
Altman Z: 5.41
Beneish M: n/a
Dividend safety: n/a

Overview

Beam Therapeutics Inc. (BEAM) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Beam Therapeutics Inc. (BEAM) trades at a P/B ratio of 2.9×. Over the past ten years it has ranged from 0.0× (March 2020) to 23.9× (December 2020); the current reading is higher than 46% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/BEAM/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Beam Therapeutics Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/BEAM/metrics/pb-ratio">Beam Therapeutics Inc. (BEAM) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	2.2×	(20.44%)
FY2024	2.8×	29.14%
FY2023	2.2×	(39.51%)
FY2022	3.6×	(42.46%)
FY2021	6.2×	(60.15%)
FY2020	15.5×	—
FY2019	0.0×	—

Period	P/B ratio	Change
Sep 2026	2.7×	(19.89%)
Jun 2026	3.4×	58.73%
Mar 2026	2.1×	(4.55%)
Dec 2025	2.2×	(14.09%)
26 more quarters	Free account

Against its own ten years

Low 0.0× High 23.9×

Ten-year median 2.9×

Current reading's percentile 45

Company	P/B ratio
TLX Telix Pharmaceuticals Limited compare	n/m
BEAM Beam Therapeutics Inc.	2.9×
IDYA IDEAYA Biosciences, Inc. compare	2.9×
NAMS NewAmsterdam Pharma Company N.V. compare	3.7×
ZLAB Zai Lab Limited Unsponsored ADR compare	4.5×
XNCR Xencor, Inc. compare	5.2×
VRDN Viridian Therapeutics, Inc. compare	5.5×
MBX MBX Biosciences, Inc. compare	5.7×
RCUS Arcus Biosciences, Inc. compare	6.4×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Beam Therapeutics Inc. (BEAM) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on BEAM

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on BEAM

Stockrow Weekly